THYROCARE TECHNOLOGIES
|
|
| BOM : 539871 NSE : THYROCARE | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : High [>50%] |
May 27,2022 |
|
Price(EOD): ₹ 690.95
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Hospital & Healthcare Services |
| MCap: ₹ 3,655.13 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| THYROCARE TECHNOLOGIES | 6.1% | -15.6% | -31.1% |
| APOLLO HOSPITALS ENTERPRISE | 3.8% | -14.6% | 14.6% |
| MAX HEALTHCARE INSTITUTE | 2.3% | -9% | 57.5% |
| DR LAL PATHLABS | 11.4% | -20.8% | -27.4% |
| FORTIS HEALTHCARE | -3.2% | -13.9% | 5.7% |
| METROPOLIS HEALTHCARE | -5.3% | -30% | -30.6% |
| ASTER DM HEALTHCARE | 13.4% | 0.4% | 28% |
| NARAYANA HRUDAYALAYA | 3.5% | -7.7% | 51.9% |
| KRISHNA INSTITUTE OF MEDICAL SCIENCES | -2% | -3.8% | NA |
FUNDAMENTAL ANALYSIS OF THYROCARE TECHNOLOGIES
[ Q(TTM): Mar2022, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF THYROCARE TECHNOLOGIES
[As on : May 27,2022
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
32.29
P/E Calculated based on EPS of 21.4
[ Mar2021 - Consolidated Results ] 8.61
P/B Calculated based on Book Value of 80.26
[ Mar2021 - Consolidated Results ] 6.21
P/S Calculated based on Revenues of 588.82 Cr
[ TTM - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-3% -36% -44% |
SHARE PRICE MOMENTUM OF THYROCARE TECHNOLOGIES
THYROCARE TECHNOLOGIES vs SENSEX
DEBT OF THYROCARE TECHNOLOGIES
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2021 2020 2019 Avg_3yrs |
0 0 0 - |
0 0.01 0.01 0.01 |
|
[Last Annual Data : Mar2021]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF THYROCARE TECHNOLOGIES
| Pledged Promoter Shares |
100 % | |
|---|---|---|
| As on : Mar2022 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF THYROCARE TECHNOLOGIES
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
11.21% 2.15% 2.08% -4.52% |
-11.09% -27.05% -37.83% -44.85% |
| QtrlyTrend |
-2 | |
| Latest Qtr: Mar2022 | ||
| Quarterly Result Analysis → | ||
THYROCARE TECHNOLOGIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE 500 | -0.1% | -6.8% | 7.2% |
| S&P BSE ALLCAP | -0.3% | -7.1% | 7.5% |
| S&P BSE 400 MIDSMALLCAP | -1.3% | -9.3% | 7.2% |
| S&P BSE MIDSMALLCAP | -1.5% | -10.1% | 7.1% |
| S&P BSE HEALTHCARE | -2% | -8.1% | -8.7% |
| S&P BSE SMALL CAP | -2.8% | -11.4% | 10% |
| S&P BSE 250 SMALLCAP | -2.9% | -12.2% | 6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | -0.2% | -6.9% | 7% |
| NIFTY500 MULTICAP 50:25:25 | -0.8% | -8.3% | 7.2% |
| NIFTY MID SMALL400 | -1.5% | -9.7% | 7.3% |
| NIFTY SMALLCAP250 | -3% | -12.7% | 6.4% |
You may also like the below Video Courses
FAQ about THYROCARE TECHNOLOGIES
Is THYROCARE TECHNOLOGIES good for long term investment?
As on May 27,2022, the Fundamentals of THYROCARE TECHNOLOGIES look Strong and hence it may be good for long term investment! See Financial Performance of THYROCARE TECHNOLOGIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is THYROCARE TECHNOLOGIES UnderValued or OverValued?
As on May 27,2022, THYROCARE TECHNOLOGIES is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of THYROCARE TECHNOLOGIES ?
As on May 27,2022, the Intrinsic Value of THYROCARE TECHNOLOGIES is Rs. 1,087.08 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 709.10
Fair Value [Median EV / Sales Model] : Rs. 1,087.08
Fair Value [Median Price / Sales Model] : Rs. 1,229.42
Median Fair Value of THYROCARE TECHNOLOGIES : Rs. 1,087.08
Is THYROCARE TECHNOLOGIES trading at a Premium or Discount?
As on May 27,2022, THYROCARE TECHNOLOGIES is trading at a Discount of -36% based on the estimates of Median Intrinsic Value!
Check out Annual Financials of Industry Peers
Check out Quarterly Results of Industry Peers
Compare Analytics
APOLLO HOSPITALS ENTERPRISE LTD vs MAX HEALTHCARE INSTITUTE LTD vs DR LAL PATHLABS LTD
FORTIS HEALTHCARE LTD vs METROPOLIS HEALTHCARE LTD vs ASTER DM HEALTHCARE LTD
NARAYANA HRUDAYALAYA LTD vs KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD vs THYROCARE TECHNOLOGIES LTD
SHALBY LTD vs KOVAI MEDICAL CENTER & HOSPITAL LTD vs KMC SPECIALITY HOSPITALS (INDIA) LTD
INDRAPRASTHA MEDICAL CORPORATION LTD vs KAYA LTD vs ARTEMIS MEDICARE SERVICES LTD
APOLLO HOSPITALS ENTERPRISE LTD vs MAX HEALTHCARE INSTITUTE LTD vs DR LAL PATHLABS LTD
FORTIS HEALTHCARE LTD vs METROPOLIS HEALTHCARE LTD vs ASTER DM HEALTHCARE LTD
NARAYANA HRUDAYALAYA LTD vs KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD vs THYROCARE TECHNOLOGIES LTD
SHALBY LTD vs KOVAI MEDICAL CENTER & HOSPITAL LTD vs KMC SPECIALITY HOSPITALS (INDIA) LTD
INDRAPRASTHA MEDICAL CORPORATION LTD vs KAYA LTD vs ARTEMIS MEDICARE SERVICES LTD
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].
